Hormone Replacement Therapy (HRT) raises many questions among women experiencing menopause. In this article, you will find up-to-date information on the benefits, risks, and alternatives to HRT, based on the latest research.
HRT in menopause – check facts, benefits, risks, and alternatives. An up-to-date review of research on hormone replacement therapy for women.
Table of Contents
- What is hormone replacement therapy in menopause?
- Benefits of HRT for women in menopause
- Main risks and contraindications of HRT
- Diet and alternatives to hormone replacement therapy
- Who is HRT recommended for? Indications and individual qualification
- Facts and myths about HRT – what does research say?
What is hormone replacement therapy in menopause?
Hormone Replacement Therapy (HRT), also called menopausal hormone therapy, is a form of treatment involving the administration of female sex hormones – primarily estrogen, sometimes combined with progestogen – to alleviate symptoms resulting from ovarian failure in perimenopausal and postmenopausal women. In the natural menstrual cycle, estrogens and progesterone are mainly produced by the ovaries. As menopause approaches, their levels become unstable and then decrease significantly, causing characteristic complaints such as hot flashes, night sweats, vaginal dryness, mood swings, sleep problems, decreased libido, and, in the longer term, accelerated bone loss and increased risk of osteoporosis. The core idea of HRT is to partially “recreate” what the female body produced before menopause, but in a controlled, strictly adjusted dose, to provide symptom relief and improve quality of life on one hand, and to minimize possible side effects on the other. Different regimens and administration routes are used in clinical practice. Estrogen may be taken orally (tablets), transdermally (patches, gels, sprays), vaginally (suppositories, creams, tablets), or more rarely by injection. For most women with a uterus, progestogen (a synthetic equivalent of progesterone) is added to estrogen to protect the endometrium from excessive growth, which could otherwise increase the risk of endometrial cancer over time. Women who have undergone hysterectomy (uterus removal) usually receive estrogen only, as endometrial protection is no longer necessary.
It is important to distinguish between classic systemic HRT and local treatments. Systemic therapy (e.g., pills, patches) affects the whole body and is used mainly when symptoms are widespread and severe, such as intense hot flashes or serious sleep disturbances. In contrast, vaginal preparations containing low doses of estrogen or derivatives act locally on the vaginal and vulvar mucosa, easing dryness, pain during intercourse, and recurrent intimate infections, with minimal absorption into the bloodstream. This form of therapy is also recommended for women who do not qualify for full HRT due to contraindications but struggle with distressing urogenital symptoms.
Thus, HRT is not a single “ready-made product” but rather a broad term covering various combinations of hormones, doses, and forms of administration, individually tailored by the physician to the patient’s age, time since menopause, severity of symptoms, comorbidities, and personal cardiovascular and oncological risk profile.
The contemporary approach to HRT differs significantly from two or three decades ago. Today, it is considered one of several possible management strategies, not a universal remedy for every menopausal woman. Its main goal remains the alleviation of moderate and severe vasomotor symptoms (hot flashes, night sweats), which can seriously disrupt work, family life, and intimate relationships. HRT also helps stabilize mood, reduce nighttime awakenings, and improve sleep, indirectly leading to better concentration, intellectual performance, and daily well-being. Another important aspect is bone health—estrogens have a proven effect in reducing bone resorption, while their sharp decline after menopause speeds up the aging process. Properly conducted HRT can help minimize bone mineral density loss and reduce the risk of osteoporotic fractures, although, following current guidelines, it is not the first-line treatment solely for bone protection—especially in older patients.
It is crucial to use the proper terminology: HRT is a symptomatic therapy, not a “rejuvenation cure” or a means to halt the body’s aging. It does not restore fertility, reverse the biological age of ovaries, nor is it recommended haphazardly for every woman “just in case.” According to current guidelines, it is recommended primarily for women in the perimenopausal period and up to about age 60, when the benefits of therapy (symptom relief, improved quality of life) outweigh potential risks. The so-called “therapeutic window” is crucial—it is assumed that starting HRT within 10 years of the last period and before age 60 is generally associated with a better safety profile than starting at a much older age. In practice, before a woman begins hormone therapy, the doctor should take a detailed history (including family history of heart disease, stroke, thrombosis, breast and endometrial cancer), perform a gynecological exam, check blood pressure, order appropriate laboratory and imaging tests (such as a mammogram at the recommended age), and clarify potential benefits and risks. Only then can the right product (estrogen alone or with progestogen, continuous versus sequential regimen), administration form (oral, transdermal, vaginal), and expected duration be selected. HRT is thus a wide concept: it includes systemic treatment, focused on alleviating distressing symptoms and preventing bone loss, and local therapy, mainly for vaginal and urinary issues. In any case, it is a medical intervention that should be considered individually—in the context of age, lifestyle, health history, and personal expectations for treatment.
Benefits of HRT for Women in Menopause
HRT is one of the most thoroughly studied methods of relieving menopausal symptoms and improving quality of life in this challenging period. The most obvious and rapid benefit is a reduction in vasomotor symptoms, i.e., hot flashes and night sweats. For many women, especially in early menopause, systemic HRT (in pills, patches, or gels) can reduce the frequency and severity of hot flashes within weeks, leading to better sleep, less daytime fatigue, and increased work effectiveness. Research shows that hot flashes are not just a discomfort—untreated, they disrupt sleep architecture, affect memory, concentration, mood, and may even increase the risk of depression. By stabilizing body temperature fluctuations, HRT can indirectly improve cognitive functioning, reduce irritability, and the so-called “brain fog” that many women experience around menopause.
Another important benefit is HRT’s impact on sexual health and quality of sex life. Decreased estrogen causes vaginal dryness, thinning, and loss of elasticity of the epithelium, itching, pain during intercourse, and more frequent intimate infections. Topical HRT (suppositories, creams, vaginal rings) acts directly on tissues, improving blood flow and lubrication, increasing mucus production, thereby reducing pain and discomfort during intercourse. In many cases, this translates into renewed sexual satisfaction, greater intimacy in relationships, and better mental wellbeing. For some women, combining local with systemic therapy is necessary, which further stabilizes mood and libido. Modern treatment protocols emphasize that sexual health in menopause is not a luxury, but an important aspect of wellbeing, and HRT has a real, clinically documented effect in this area.
Main Risks and Contraindications of HRT
Although HRT can bring numerous benefits, it is not without risks. Understanding potential dangers and contraindications is essential before starting treatment. HRT risks depend on factors like age, time since last period, type and dose of hormones used, route of administration (oral, transdermal, vaginal), as well as individual health and family circumstances. One frequently discussed risk is increased likelihood of venous thrombosis and pulmonary embolism, especially in the early years of HRT and in women with additional risk factors (obesity, smoking, congenital thrombophilia, prolonged immobility). Oral estrogen, in particular, is more likely to impact coagulation than transdermal forms (patches/gels), so the latter may be recommended for some women. The risk of thromboembolic events is also higher in those starting HRT after age 60 or more than 10 years post-menopause. Another concern is HRT’s impact on hormone-dependent cancers, especially breast cancer and endometrial cancer. For women with a uterus, estrogen and progestogen must be combined to protect the endometrium from overgrowth, which over time increases the risk of endometrial cancer. Estrogen alone systemically is reserved for women after hysterectomy. Regarding breast cancer, studies show that long-term (usually over 5 years) combined estrogen-progestogen therapy can slightly increase cancer risk, especially among women already at higher risk (family history, BRCA mutations, previous atypical breast lesions). Importantly, this risk varies among regimens and types of progestogens; some evidence suggests natural progesterone and some progestogens may be safer. HRT can also affect breast tissue density in imaging (mammograms), sometimes making results harder to interpret and requiring more frequent checks.
Cardiovascular risk must also be considered. For women who start HRT within the “therapeutic window” (typically up to age 60 or within 10 years since menopause), therapy does not increase the risk of heart attack or stroke, and in some groups may even have a neutral or mildly protective effect. The situation changes for older women, those with established atherosclerosis, or those who have had a heart attack or stroke—in those cases, the risk of cardiovascular complications increases, so hormonal therapy is generally discouraged or considered very cautiously. Blood pressure must also be monitored—although HRT does not necessarily cause hypertension, it requires careful control, and significant pressure fluctuations may require therapy modification or discontinuation. Common, usually mild side effects include breast tenderness or swelling, spotting or bleeding (especially in the first months), bloating, headaches, mood swings, fluid retention, or weight gain. These symptoms often subside with dose adjustment or switching regimens or forms. Absolute contraindications include: active or historical breast cancer or other hormone-dependent cancers, unexplained vaginal bleeding, active or previous venous thrombosis or pulmonary embolism, recent heart attack or stroke, severe hepatic disease, and late-onset porphyria. Care is needed for women with migraine with aura, severe hypertriglyceridemia, gallstones, endometriosis, uterine fibroids, benign breast disease, and a family history of breast cancer or thromboembolism. In such cases, HRT consideration is always individual and based on thorough diagnosis. Key are regular check-ups: gynecological exams, pelvic ultrasound, mammography or breast ultrasound as recommended, lipid profile, liver enzymes, venous assessment, and blood pressure. Patients should be advised which symptoms demand immediate consultation: sudden pain and swelling in the leg, shortness of breath, acute chest pain, sudden visual or speech disturbances, severe unusual headaches, abnormal vaginal bleeding, or palpable breast lumps. Careful monitoring, proper qualification for therapy, and regular adjustments minimize risks and allow HRT to be used as safely as possible.
Diet and Alternatives to Hormone Replacement Therapy
Not every woman can or wants to use HRT, which is why there’s growing interest in non-pharmacological methods and lifestyle changes that can ease menopausal symptoms. Diet plays a key role—proper composition can support hormonal balance, stabilize weight, improve sleep quality, and benefit bone and heart health. The basis is the so-called Mediterranean diet: rich in vegetables, fruits, whole grains, legumes, olive oil, nuts, seeds, and fatty sea fish, which supply omega-3s with anti-inflammatory and cardiovascular benefits. Regular consumption of cruciferous vegetables (broccoli, cabbage, kale) helps regulate estrogen metabolism, and fiber-rich foods help maintain stable glucose and insulin, indirectly benefiting mood and hunger control. Products rich in calcium and vitamin D are also crucial—fermented dairy, calcium-fortified tofu, green leafy vegetables, sun exposure, and possible vitamin D supplementation after consulting a doctor—to help prevent osteoporosis, especially if a woman doesn’t use HRT. Increasingly, the role of phytoestrogens—plant compounds similar to estrogen, found mainly in soy, red clover, flax, and certain legumes—is discussed. Studies show a moderate effect of soy isoflavones in reducing hot flash frequency, although results are weaker than classic HRT and appear only after months of regular intake. It’s worth noting that, for women with a history of hormone-dependent breast cancer, high-dose phytoestrogen supplements should be discussed with an oncologist. Instead of supplements, moderate intake of natural foods—tofu, tempeh, soy milk fortified with calcium, ground flaxseed in oatmeal or smoothies—is preferred. It’s also wise to limit highly processed foods, simple sugars, trans fats, and excessive alcohol, which can worsen inflammation, mood swings, and weight control. Some women find vasomotor symptoms (hot flashes, facial flushing) worsen after very spicy foods, hot drinks, coffee, or alcohol—keeping a diary may help identify and limit personal “triggers.” Proper hydration is as vital as diet, especially if night sweats or headaches are present, as are regular meals for glycemic stability. Increasing attention is paid to gut microbiota—a fiber-rich diet, pickles, natural yogurt, and kefir support “good” gut bacteria, potentially influencing estrogen metabolism and general immunity.
Besides diet, there are many alternatives and supplements to HRT that can be used alone or alongside hormonal therapy (if approved by a doctor). Well-studied options include local vaginal preparations with low estrogen or hyaluronic acid, which act mainly at the site—minimizing dryness, itching, pain during intercourse, and infection risk, with minimal systemic exposure. For women who cannot use estrogen, non-hormonal vaginal moisturizers and lubricants with physiological pH and osmolality are available to avoid mucosal irritation. To manage mood swings, anxiety, or insomnia, official guidelines include certain non-HRT medications—low-dose antidepressants (SSRIs, SNRIs), gabapentin, or clonidine—which can reduce hot flashes and improve life quality, especially in women for whom HRT is contraindicated. Non-pharmaceutical interventions are increasingly recommended: regular physical activity (resistance training, walking, Nordic walking, yoga, pilates) improves cardiorespiratory fitness, bone health, reduces stress, and supports better sleep. Relaxation techniques—mindfulness meditation (mindfulness), breathing exercises, Jacobson’s training, yoga nidra—help lower sympathetic activity and subjective perception of hot flashes and tension. Cognitive-behavioral therapy (CBT) for menopause symptoms has strong evidence, teaching strategies to manage insomnia, anxiety, negative thoughts about aging, and bodily changes. Herbs and dietary supplements (e.g., black cohosh, vitex, evening primrose, lemon balm, hops) are also popular; however, research on their effectiveness is often limited, and active substance content varies between brands. Herbal remedies may also interact with medicines (e.g., St. John’s wort with antidepressants or anticoagulants), so any “natural” remedies should be discussed with a doctor or pharmacist. An emerging area includes so-called SERMs (selective estrogen receptor modulators), which may protect bones and certain tissues without classic systemic estrogen effects, as well as “menopausal” supplements combining calcium, vitamin D, K2, magnesium, and B vitamins—they are not a replacement for HRT but do support the skeletal and nervous systems.
Women choosing alternatives should have realistic expectations: non-pharmacological methods generally act more gently and slowly than HRT, require consistency, and often combining several strategies—diet change, exercise, and psychological support—and safety and selection should always be discussed with a specialist, ideally a gynecologist or endocrinologist specializing in menopause.
Who Is HRT Recommended For? Indications and Individual Qualification
Hormone Replacement Therapy is not a “cure for menopause” for every woman, but a targeted medical tool most effective in selected clinical situations. The most classic indication for HRT is moderate to severe vasomotor symptoms—hot flashes, night sweats, sudden heat waves, heart palpitations, or sleep disturbances—that substantially lower quality of life and impede daily functioning. In such cases, especially where lifestyle modification and non-pharmaceutical methods do not provide relief, HRT is considered first-line therapy by most scientific societies (including NAMS, EMAS). Equally important are severe urogenital symptoms—dryness, burning, itching of the vagina, painful intercourse, recurring infections, and urinary incontinence. Treatment usually starts with topical estrogen preparations, which act locally and have a very low systemic exposure, but for some, especially if vasomotor symptoms are also present, systemic HRT is considered. Another major group is women with premature ovarian insufficiency or early menopause (before age 40, or between 40 and 45).
For this population, HRT not only reduces symptoms but also helps prevent long-term consequences of estrogen deficiency—osteoporosis, cardiovascular disease, metabolic disorders, and potentially cognitive impairment. Therapy is usually recommended to continue until the typical age of natural menopause unless contraindicated. Another often-overlooked indication is cancer-related bone loss and high fracture risk, particularly in early postmenopausal women with reduced bone density (osteopenia, osteoporosis) and other risk factors (low body weight, smoking, long-term steroid therapy, family history of hip fractures). In this group, HRT may be an option among antiresorptive agents, with choice based on age, risk profile, and vasomotor symptoms. Special situations include surgical menopause (removal of ovaries) at a young age, where acute, profound estrogen deficiency significantly increases cardiovascular risk and accelerates bone loss—here, HRT is usually strongly recommended unless contraindications exist. It is also worth mentioning women struggling with severe mood disturbances in the perimenopausal period—in them, in collaboration with a psychiatrist or psychologist, well-adjusted HRT can be an important adjunct, especially when mood or anxiety episodes have a hormonal basis.
The decision to initiate HRT should always result from individual qualification, not just age or time since the last period. A detailed medical history is crucial, including thromboembolic, cardiovascular (hypertension, ischemic heart disease, stroke), hormone-dependent cancers (breast, endometrial cancer), migraines, liver disease, coagulation disorders, current medications (e.g., anticoagulants), and lifestyle (smoking, obesity, physical inactivity). The doctor also assesses the patient’s age and “therapeutic window”: the best time to start HRT is within 10 years of menopause or before age 60, when the benefit-risk profile is most favorable. For those starting later—especially after age 60 and many years post-menopause—cardiovascular risk (heart attack, stroke, pulmonary embolism) is higher and requires careful analysis. Qualification routinely includes basic tests: blood pressure, body mass and BMI, lipid profile, glucose, liver function, sometimes clotting parameters; before starting HRT, updated cervical cytology, gynecological ultrasound, and for women in the right age group—mammogram or breast ultrasound—are also recommended. This assesses both absolute contraindications (current or previous breast cancer, unexplained vaginal bleeding, active thromboembolic disease, severe liver disease) and relative contraindications that may require modification of treatment form, dose, or close supervision.
Therapy individualization covers your regimen (estrogen monotherapy for women post-hysterectomy, or estrogen plus progestogen for women with uterus), route (oral, transdermal, vaginal), and the lowest effective dose to relieve symptoms with acceptable safety. Shared decision-making is crucial—the doctor should discuss real benefits and potential risks, taking into account patient priorities (reducing hot flashes vs. osteoporosis prevention, convenience, fear of weight gain or breast cancer).
Individual qualification does not end at therapy initiation—regular check-ups are needed (usually every 6–12 months), assessing effectiveness, side effects, updating benefits and risks, and possibly adjusting dose or form, as well as periodically reappraising whether HRT is still needed and in what scope. With such an approach, HRT becomes an informed, personalized choice, and not an automatic part of the “menopause package.”
Facts and Myths About HRT – What Does Research Say?
Hormone Replacement Therapy has sparked emotion for years, mostly due to incomplete understanding of research results and their often simplified interpretation in the media. One of the most repeated myths is that “HRT is dangerous for every woman”, fueled by reports such as the Women’s Health Initiative (WHI) study in the early 2000s. Early headlines highlighted increased risk of breast cancer, thrombosis, and cardiovascular events in all women, without emphasizing that the affected group consisted of older women (average age 63), many years post-menopause, often already with cardiovascular risk factors. Subsequent WHI analyses and newer studies show that starting HRT in younger women, within the “therapeutic window” (before age 60 or within 10 years post-menopause), is associated with a different safety profile—in this group, there is no clear increased risk of cardiovascular complications, and in some analyses, HRT has a neutral or slightly positive cardiovascular effect. Studies do confirm that HRT increases venous thromboembolism risk, especially in the first treatment year, but this risk is much lower with transdermal (patch, gel) than oral preparations. Another myth is that “HRT always causes breast cancer.” Research presents a subtler picture: for women on combined therapy (estrogen + progestogen) for several years, breast cancer risk rises slightly, but the absolute increase is similar or less than with obesity, high alcohol intake, or sedentary lifestyle. Estrogen alone (for post-hysterectomy women), in several large analyses, did not increase breast cancer risk, and some studies even showed a decrease.
Duration matters—short-term therapy (up to 3–5 years) in healthy women with severe symptoms has a different risk profile than long-term unsupervised hormone use. Another myth is that HRT “always harms the heart.” Research-based guidelines suggest that in younger symptomatic women without atherosclerosis, starting HRT at the right time may be neutral, or even improve lipid profiles and vascular elasticity. By contrast, in women who begin after age 60, years post-menopause, vascular benefits are smaller and the risk of cardiovascular incidents greater. It is also a myth that “HRT always causes great weight gain.” Studies do not support hormones as the main cause of weight gain; metabolic changes due to aging and menopause are more likely. For some women, hormone stabilization may even help maintain physical activity and good sleep, indirectly aiding body weight control. Another frequent myth is that “herbal products and phytoestrogens are just as effective as HRT, but without risk.” Studies show that while phytoestrogens (e.g., soy, red clover) may mildly reduce hot flashes for some, their effectiveness is clearly less than hormone therapy, and the safety of high-dose, long-term use is not as well-studied as classic HRT. Supplements also vary in composition and active compound content between batches, making effects unpredictable. The idea that “if it’s just a low hormone dose, no check-ups are needed” is especially dangerous—any hormone therapy requires initial diagnosis (including family history of heart or cancer, breast assessment, blood pressure, gynecological exam, endometrial assessment if needed) and regular follow-up. Studies conclusively show that careful qualification and choice of administration (oral, transdermal, vaginal), dose, and progestogen type critically affect safety.
Bone health is another area of myth: “HRT doesn’t matter for osteoporosis prevention, calcium and vitamin D are enough.” Clinical trials clearly show that properly managed HRT slows bone mass loss and lowers risk of osteoporotic fractures, especially spine and hip, and especially if started around menopause. Calcium and vitamin D supplementation is still important, but usually insufficient alone—especially in high fracture-risk women. However, after discontinuing HRT, bone loss can accelerate again, so long-term prevention requires combining various strategies (diet, exercise, possibly other bone medications).
Another myth is that HRT affects cognition: some say “HRT prevents dementia,” while others claim it “increases Alzheimer’s risk.” The truth is more measured: short-term HRT started around menopause can improve sleep, concentration, and perceived mental sharpness (also via better hot flash and mood control), but there is no definite evidence for long-term dementia protection. In studies begun in much older women, years post-menopause, HRT could even raise risk of vascular dementia and Alzheimer’s, underlining the importance of when therapy is started. It is not true that “HRT is only effective in tablet form”—numerous studies show that transdermal forms (patches, gels) provide comparable relief of vasomotor symptoms and bone protection, with less coagulation and liver metabolism effect. For complaints limited to intimate areas (dryness, pain on intercourse, infections), evidence is clear that local, low-dose vaginal estrogen is highly effective with minimal systemic absorption, so does not significantly increase risk of thrombosis or breast cancer.
It is also untrue that “HRT always worsens bleeding and cycles.” Therapy regimens are constructed to suit the patient: premenopausal women may use sequential protocols with predictable withdrawal bleeding, and postmenopausal women are usually offered continuous regimens, often leading to complete absence of bleeding after adaptation. Irregular spotting is common at therapy start and typically resolves after a few months or with dose/progestogen modification.
Another false notion is that “HRT is a matter of comfort or whim,” while data show that untreated severe menopausal symptoms (especially hot flashes disturbing sleep, severe mood disorders, painful sex) worsen work productivity, family relations, mental health, and overall health prognosis. Quality-of-life studies show significant improvements for women on well-matched HRT, especially if other methods have failed. Science thus disproves both the overly negative image of HRT as “a dangerous drug for every woman” and the overly optimistic vision of it as a “fountain of youth” without side effects, emphasizing individual risk-benefit assessment based on current guidelines and reliable studies.
Summary
Hormone Replacement Therapy (HRT) is an effective way to relieve menopausal symptoms and improve the quality of life for many women. However, individual qualification and careful consideration of both potential benefits and risks, such as osteoporosis or cancer risk, are crucial. Changes in diet and natural ways of supporting the body can be alternatives. Medical support and access to reliable information are important—only then can a woman make an informed choice. The latest research debunks many myths and shows who benefits most from HRT and in what circumstances.
